1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Insomnia Therapeutics Market Analysis By Treatment Type [Devices, Drugs ], By Sales Channel And Segment Forecasts, 2014 - 2025

Insomnia Therapeutics Market Analysis By Treatment Type [Devices, Drugs ], By Sales Channel And Segment Forecasts, 2014 - 2025

  • October 2017
  • 101 pages
  • ID: 5214705
  • Format: PDF
  • By Grand View Research

Summary

Table of Contents

Insomnia Therapeutics Market Analysis By Treatment Type [Devices, Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists)], By Sales Channel, And Segment Forecasts, 2014 - 2025

The global insomnia therapeutics market is expected to reach USD 3.45billion by 2025, according to a new report by Grand View Research, Inc.

The market is primarily driven by thepresence of patented molecules, potential clinical pipeline candidates, rising stress level,and increase in geriatric population who find it difficult to fall asleep. Increase in prevalence of insomnia &awareness about this conditionand availability of safer drugs are anticipated to fuel revenue growth.

Insomnia is estimated to affect approximately 35% of the global population. Differentpatternsof the condition include difficulty in sleep initiation and maintenance, which is generally accompanied with frequent awakenings&awakening too early with trouble sleepingagain. Long-terminsomnia can hamper everyday life, which may result in nonproductive work hours. If left untreated, this conditionmay lead to severe depression and nervous breakdown of the patient.

Factors influencing insomnia therapeutics market growth includerising stress level, presence of patented molecules in the market, potentialdrugs in clinical pipeline, introduction of technologically advanced medical devices, and growinggeriatric population.Growing awareness about the impact of sleep deprivation on everyday lifeis anticipated to increaseadoption rate of various treatments for insomnia, which is expected to lead to revenue growth of the insomnia therapeutics market.

Currently, widely adopted treatment options for insomnia include generic nonbenzodiazepines and antidepressants even though other novel agents such as orexin antagonists and melatonin antagonists are available in the market.Launch of Eisai’s Lemborexant is expected to cater to unmet medical needs in this segment and fuel growth of this market over the forecast period. According toUnited Nations (UN) report in 2015, population in the age group of 60 years and above is projected to grow by 56% and is expected to reach around 1.4 billion by 2030. These statistics indicate the growing geriatric population. Since this population base is more susceptible to sleep deprivation, the demand for insomnia therapeutics is anticipated to increase.

Further Key Findings From the Report Suggest:
• North America held majority of the share in 2016 due to increase inawareness about diseases, growing geriatricpopulation, and high adoption of therapeutics for treatment.
• The U.S. dominated North America owing to the presence of largest sleep-deprived population and use of patented drugs for treatment.
• Japan is the second largest market after the U.S. Asia Pacific is expected to be the fastest growingmarket due to the presence ofemerging economies like China & India and launch of new drugs.
• Some of the key players are Takeda Pharmaceutical Co. Ltd.; Vanda Pharmaceuticals; Merck & Co, Inc.;Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Mylan N. V.; Sumitomo Dainippon Pharma Co., Ltd.; Sanofi; Paratek Pharmaceuticals;and Ebb Therapeutics.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on